Latest Nilotinib News & Updates

US-Based Cipla Subsidiary Recalls Anti-Cancer Medicine Over Manufacturing Issue

By

New Delhi, March 8 (IANS) A US-based subsidiary of Cipla has recalled more than 400 cartons of a generic anti-cancer medicine due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).In its latest enforcement report, the US health regulator said that Cipla USA, Inc, based in Warren, New Jersey, is recalling certain batches of Nilotinib Capsules in two strengths — 150 mg and 200 mg.The recall involves 271 cartons of one batch and 164 cartons of another batch of the …